NIPT available as standard option for all pregnant women from 1 April From 1 April 2023, the Non-Invasive Prenatal Test (NIPT) will be available to all pregnant women. They do not have to take part in a scientific study for this.
COVID-19 less severe due to Omicron variants, vaccinations and previous infections The consequences of infections involving the coronavirus SARS-CoV-2 are decreasing. This is because nearly everyone in the Netherlands has built up immunity to COVID-19 as a result of vaccination and/or previous infection, and because the current Omicron variants are less likely to cause serious illness.
Young people less likely to contact GP for mental health problems The percentage of young people who report having mental health problems has hardly decreased since the last lockdown (in early 2022).
Initial response to Safety Board report on COVID-19 crisis The Dutch Safety Board (OVV) has published its report ‘Approach to the COVID-19 crisis - Part 2: September 2020 to July 2021’. The report also includes a recommendation for RIVM. ANP
Cancer screening programmes now more accessible to transgender and intersex persons Since October 2022, is it has become easier for transgender and intersex persons to take part in cervical cancer screening and breast cancer screening. Transgender and intersex persons with a uterus and/or breast tissue can register with Bevolkingsonderzoek Nederland.
Upward trend in COVID-19 figures continues: extra risk for vulnerable groups The upward trend in COVID-19 figures continues to rise in the Netherlands. The increase is visible in all areas. The number of nursing home residents who tested positive for COVID-19 rose by 23% last week. Hospitals are also admitting more and more people due to COVID-19.
Upward trend in SARS-CoV-2 infections continues Infections with the coronavirus SARS-CoV-2 are continuing to increase in the Netherlands. More and more people with COVID-19 are turning up in the test lanes of the Municipal Public Health Services (GGDs), in nursing homes and in hospitals.